A

simmering clash between brand-name and generic drug makers may be reviewed by the US Supreme Court on Friday, and the outcome could determine some key procedural steps for pharmaceutical patent litigation. And this, in turn, might influence just how fast copycat drugs can get to market.

At issue is the legal concept of jurisdiction which, essentially, refers to the location of the court where a lawsuit is heard. And venues can be important, especially since some courts may be better equipped than others to sort out complex challenges to prescription drug patents.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.